Our mission is to create oral versions of the epinephrine auto-injectors such as the EpiPen to help people suffering from severe allergies to live their best possible lives with the freedom and confidence to go where they want and do what they want.
READ MORE
Anaphylaxis is a severe, potentially life-threatening allergic reaction that can occur rapidly, often within minutes of exposure to an allergen. Common triggers include certain foods, insect stings, medications, and latex. The condition is characterized by a sudden release of chemicals in the body, leading to symptoms such as swelling, hives, difficulty breathing, a drop in blood pressure, and, in severe cases, loss of consciousness. Immediate medical treatment is crucial, typically involving an injection of epinephrine, which can reverse the symptoms. Individuals at risk of anaphylaxis are often advised to carry an epinephrine auto-injector and wear medical identification to alert others to their condition.
Insignis Therapeutics is developing a groundbreaking epinephrine sublingual spray, IN-001, which has the potential to revolutionize the treatment of severe allergic reactions, including anaphylaxis. IN-001 is designed to be safe and effective, needle-free, easy to carry, and simple to use. Unlike traditional epinephrine autoinjectors or nasal spray products, which must be stored within narrow temperature ranges of 68° to 77° F (20° to 25°C), IN-001 remains chemically and physically stable across a broad temperature spectrum from -4° F to 140° F ( -20°C to 60°C).
We believe that anaphylaxis is a real-world medical emergency that demands a robust and reliable rescue medication like IN-001, which remains stable and usable under any weather conditions. Our innovative epinephrine sublingual spray, if approved, will empower people suffering from severe allergies to live their lives with greater freedom and confidence, no longer constrained by the limitations of traditional epinephrine auto-injectors. This advancement could enable those living with anaphylaxis to enjoy a normal, active lifestyle without the constant fear of life-threatening allergic reactions, which we believe is both empowering and liberating.
Insignis Therapeutics is a privately held specialty pharmaceutical company focused on developing innovative allergy and anaphylaxis treatments.
Our team has a proven track record of clinical development and new drug approvals.
Mingbao Zhang, PhD, Prior to founding Insignis Therapeutics, Mingbao started 3RServices LLC, a drug development CRO serving the biotech/pharmaceutical industry since 2013. He has over 25 years of hands on drug development experience previously having worked at Bayer,...
READ MORE
Raymond Glowaky, PhD, Vice President, Pharmaceutical OperationsPrior to joining Insignis, Ray was Executive Director, Drug Development at Marinus Pharmaceuticals. Ray is an experienced pharmaceutical industry scientist, with expertise in chemistry and drug development. Ray has most recently led the process chemistry...
READ MORE
Elizabeth (Bette) Monnot-Chase, PhD, Executiv Director, Analytical Chemistry/CMCBette is a highly accomplished professional with over 25 years of pharmaceutical industry experience supporting the development of novel therapeutical agents. Her background includes strategic planning, project/laboratory management,...
READ MORE
MJun Xu, DirectorJun is the co-founder and CEO of Pharmacin, a drug development company headquartered in Shenzhen, China. Jun has over 15 years of experience in major international pharmaceutical companies including Novartis and Boehringer Ingelheim in drug discovery ...
READ MORE
Clarence Kwan, Board ObserverClarence Kwan, CAIA, CPA, has over 40 years of financial advisory and management experience in the U.S., China and Eastern Europe. Since the mid-1980's, he has been advising U.S., Chinese, and other global companies on cross border investments...
READ MORE
Epinephrine is the only drug approved for the emergency treatment of anaphylaxis. Epinephrine needs to be administered as soon as symptoms of a severe allergic reaction occurs...
+
Empowering anaphylaxis patients involves equipping them with the knowledge, tools, and confidence to manage their condition effectively and independently...
+
